Bioventus entered into a collaboration agreement with MTF Biologics to co-develop a next-generation placental tissue product to treat musculoskeletal conditions, initially focusing on knee osteoarthritis.
“We also expect to work together to develop additional uses and indications for this product as part of this program,” said Tony Bihl, CEO, Bioventus. “There is a promising and growing body of preclinical and clinical evidence underscoring the potential of these preparations in supporting the body’s natural healing processes thanks to the inherent growth factors and regulatory molecules present in placental tissues.”
Source: Bioventus
Bioventus entered into a collaboration agreement with MTF Biologics to co-develop a next-generation placental tissue product to treat musculoskeletal conditions, initially focusing on knee osteoarthritis.
“We also expect to work together to develop additional uses and indications for this product as part of this...
Bioventus entered into a collaboration agreement with MTF Biologics to co-develop a next-generation placental tissue product to treat musculoskeletal conditions, initially focusing on knee osteoarthritis.
“We also expect to work together to develop additional uses and indications for this product as part of this program,” said Tony Bihl, CEO, Bioventus. “There is a promising and growing body of preclinical and clinical evidence underscoring the potential of these preparations in supporting the body’s natural healing processes thanks to the inherent growth factors and regulatory molecules present in placental tissues.”
Source: Bioventus
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.